64Cu-SAR-bisPSMA PET Scan for Prostate Cancer
(CLARIFY Trial)
Trial Summary
What is the purpose of this trial?
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Do I have to stop taking my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking any high energy gamma-emitting radioisotopes, you must stop them at least 5 half-lives before the trial starts.
What data supports the idea that 64Cu-SAR-bisPSMA PET Scan for Prostate Cancer is an effective treatment?
The available research shows that 64Cu-SAR-bisPSMA is effective in detecting prostate cancer. One study found that it successfully identified cancer in different stages, including in lymph nodes and bones. Another study demonstrated that 64Cu-SAR-bisPSMA had a high level of accuracy in imaging prostate cancer, making it a promising option for diagnosing the disease. Additionally, it was shown to be stable and effective in targeting cancer cells in both lab and animal studies. Compared to other imaging methods, 64Cu-SAR-bisPSMA allows for later imaging, which can be beneficial for detailed diagnosis.12345
What safety data exists for 64Cu-SAR-bisPSMA PET Scan for Prostate Cancer?
The safety data for 64Cu-SAR-bisPSMA and related compounds indicate high serum stability and specific tumor uptake, with rapid clearance from non-target organs like the kidneys. Studies have shown that 64Cu-labeled PSMA ligands are promising for targeting and visualizing PSMA-positive tumors, with high contrast in imaging and potential for therapy planning. The compounds have demonstrated low toxicity in preclinical models, suggesting they are safe for further clinical evaluation.14678
Is the 64Cu-SAR-bisPSMA PET scan a promising treatment for prostate cancer?
Yes, the 64Cu-SAR-bisPSMA PET scan is a promising treatment for prostate cancer. It uses a special tracer that targets prostate cancer cells, allowing doctors to see the cancer clearly in scans. This helps in planning effective treatments and can also be used for therapy, making it a valuable tool in managing prostate cancer.13467
Research Team
Clarity Pharmaceuticals
Principal Investigator
Clarity Pharmaceuticals
Eligibility Criteria
This trial is for men at least 18 years old with high-risk prostate cancer, as defined by specific clinical stages, grade groups, or PSA levels. Participants must be planning to undergo radical prostatectomy with lymph node dissection and have not received prior treatment for their confirmed adenocarcinoma of the prostate.Inclusion Criteria
Treatment Details
Interventions
- 64Cu-SAR-bisPSMA (Cancer Imaging Agent)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Clarity Pharmaceuticals Ltd
Lead Sponsor